JP2023518905A5 - - Google Patents

Info

Publication number
JP2023518905A5
JP2023518905A5 JP2022558519A JP2022558519A JP2023518905A5 JP 2023518905 A5 JP2023518905 A5 JP 2023518905A5 JP 2022558519 A JP2022558519 A JP 2022558519A JP 2022558519 A JP2022558519 A JP 2022558519A JP 2023518905 A5 JP2023518905 A5 JP 2023518905A5
Authority
JP
Japan
Prior art keywords
antibody
kma
kappa light
composition
chains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022558519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518905A (ja
JP7817945B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000171 external-priority patent/WO2021191684A1/en
Publication of JP2023518905A publication Critical patent/JP2023518905A/ja
Publication of JP2023518905A5 publication Critical patent/JP2023518905A5/ja
Application granted granted Critical
Publication of JP7817945B2 publication Critical patent/JP7817945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022558519A 2020-03-27 2021-03-26 組成物および方法 Active JP7817945B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2020900948A AU2020900948A0 (en) 2020-03-27 Composition and method
AU2020900948 2020-03-27
US202163200752P 2021-03-25 2021-03-25
US63/200,752 2021-03-25
PCT/IB2021/000171 WO2021191684A1 (en) 2020-03-27 2021-03-26 Composition and method

Publications (3)

Publication Number Publication Date
JP2023518905A JP2023518905A (ja) 2023-05-08
JP2023518905A5 true JP2023518905A5 (cg-RX-API-DMAC7.html) 2024-04-04
JP7817945B2 JP7817945B2 (ja) 2026-02-19

Family

ID=77890984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022558519A Active JP7817945B2 (ja) 2020-03-27 2021-03-26 組成物および方法

Country Status (9)

Country Link
US (3) US20240262928A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126900A4 (cg-RX-API-DMAC7.html)
JP (1) JP7817945B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230004543A (cg-RX-API-DMAC7.html)
CN (1) CN115551877A (cg-RX-API-DMAC7.html)
AU (1) AU2021244846A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022019076A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176109A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021191684A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025213238A1 (en) * 2024-04-12 2025-10-16 HaemaLogiX Ltd Anti-kma antibody formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR617901A0 (en) * 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
AU2002344701B2 (en) * 2001-07-06 2006-03-30 Haemalogix Pty Ltd Method for treating multiple myeloma
SG175106A1 (en) * 2009-04-07 2011-11-28 Immune System Therapeutics Ltd Method for treating immune disorders
BR112012014937B1 (pt) * 2009-12-18 2021-01-19 Novartis Ag método de produção de um anticorpo, fragmento de anticorpo ou proteína de fusão fc purificada usando uma matriz de cromatografia de afinidade
WO2016031932A1 (ja) * 2014-08-27 2016-03-03 田辺三菱製薬株式会社 アルカリ洗浄によるFc領域を有するタンパク質の製造方法
BR112017018365A2 (pt) * 2015-03-13 2018-04-10 Bristol-Myers Squibb Company uso de lavagens alcalinas durante cromatografia para remoção de impurezas
IL255207B2 (en) * 2015-04-23 2023-09-01 Haemalogix Pty Ltd Myeloma antigen chimeric antigen receptors and their uses
WO2018021012A1 (ja) * 2016-07-28 2018-02-01 株式会社カネカ 抗体断片の製造方法
CN112313248A (zh) * 2018-03-29 2021-02-02 百时美施贵宝公司 纯化单体单克隆抗体的方法

Similar Documents

Publication Publication Date Title
JP6856610B2 (ja) ヘテロ二量体免疫グロブリンの精製
US5945311A (en) Method for producing heterologous bi-specific antibodies
JP2024510098A5 (cg-RX-API-DMAC7.html)
JP7187436B2 (ja) アフィニティークロマトグラフィー洗浄バッファー
JP5567691B2 (ja) Fc含有タンパク質を精製するためのクロマトグラフィー法
JP2018508188A5 (cg-RX-API-DMAC7.html)
CA3158206A1 (en) Modified immunoglobulins for targeting amyloid deposits cross-reference to related applications
JPH0566397B2 (cg-RX-API-DMAC7.html)
JPH02500329A (ja) ターゲット化多機能蛋白質
JP2025067915A5 (cg-RX-API-DMAC7.html)
RU2019109975A (ru) Способы очистки антител
JP2023545183A5 (cg-RX-API-DMAC7.html)
JP2024105229A5 (cg-RX-API-DMAC7.html)
JP2023509390A5 (cg-RX-API-DMAC7.html)
JP2021530244A5 (cg-RX-API-DMAC7.html)
EP4177274A1 (en) Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
JP2022515258A5 (cg-RX-API-DMAC7.html)
JP2023520969A5 (cg-RX-API-DMAC7.html)
CN111163804A (zh) 使用阳离子交换色谱法分离三轻链抗体
JP2021514670A5 (cg-RX-API-DMAC7.html)
JP2022536659A5 (cg-RX-API-DMAC7.html)
RU2008140947A (ru) Антитела к egfl7 и способы их применения
JP2024516098A5 (cg-RX-API-DMAC7.html)
JP2023506834A5 (cg-RX-API-DMAC7.html)
CN114341184A (zh) 抗FcRn抗体、其抗原结合片段及其医药用途